KPV: Somebody Ran the Fragment Against the Parent, and It Did Not Match

What it is

Alpha melanocyte stimulating hormone is a signalling molecule your body makes. It is 13 amino acids long, written out as SYSMEHFRWGKPV. KPV is the last three of them, lysine, proline and valine, and that is the whole compound.

It comes in two forms. One has an amide cap on the end, C16H31N5O3 at 341.45 daltons (PubChem CID 7019758), and one does not, C16H30N4O4 at 342.43 (PubChem CID 125672). The FDA nomination covers a free base and an acetate. Vendor pages do not say which form is in the vial.

What the trials found

No human trials, so everything here is rodents or cells.

The 2003 paper is the one that matters. Three researchers took alpha-MSH apart and tested the whole signal against its fragments, alongside MTII, a drug built to hit the same receptors. (PMID 12750433) In macrophages, the immune cells that swallow pathogens whole, alpha-MSH and MTII both suppressed two inflammatory signals, KC and interleukin 1 beta. KPV did nothing. Not to those signals, not to the cells.

Then they asked whether KPV touches those receptors at all, by measuring cyclic AMP, the messenger a cell puts out when a receptor fires. Switch a receptor on and cyclic AMP goes up. Block it and cyclic AMP goes down. MTII pushed it up, as expected. SHU9119, which sits on the receptor without switching it on, pushed it down, as expected. KPV moved it neither way. It was not turning the receptor on and it was not blocking it.

They took it into mice next, blocking two melanocortin receptors with SHU9119 and a second antagonist delivered into the brain, and KPV suppressed colon inflammation anyway. Same result in mice bred without a third receptor, MC1R. The authors concluded this was unlikely to run through melanocortin receptors at all, and might be about interleukin 1 beta directly.

A second team got there in 2008. KPV kept mice with colitis alive across several models of the disease, including the MC1R deficient ones. (PMID 18092346) The paper compares a range of drugs and does not give a clean dose or route.

How it gets into a cell. Your gut lining carries PepT1, a transporter whose job is hauling two and three amino acid scraps of digested food inside. KPV is three amino acids, so it rides that transporter in. (PMID 18061177) In that 2007 paper, 10 nanomolar KPV in a dish knocked down two master switches for inflammatory genes by about 40 percent across three cell lines, and 100 micromolar KPV in the drinking water suppressed two colitis models in female C57BL/6 mice. A 2016 study used the same drinking water setup to stop inflammation driven colon tumours in mice, and got nothing at all in animals bred without PepT1. (PMID 27458604)

Hold on to that last result. Take away the food transporter and the peptide stops working.

The dose figures come from delivery experiments. A 2010 study packed KPV into polymer capsules that open in the colon and needed 12,000 times less peptide than the free form to suppress inflammation. (PMID 19909746) The one clean dose per kilogram in the whole literature is 16 mcg/kg/day in mice, given by a tube into the stomach twice daily for five days, with the peptide wrapped in nanoparticles. (PMID 28143741) Two later studies used rectal gels, because a plain solution would not be absorbed that way. (PMID 34547895, PMID 35245681)

Every one of those is a delivery system built to get KPV to a specific piece of gut.

On skin, KPV crosses the barrier, sort of. Plain diffusion did not get measurable peptide into the deeper layers. Microneedles that punch tiny holes raised absorption almost 35 fold, to 4.4 mcg per square centimetre per hour. (PMID 28343991)

Nobody has published a subcutaneous injection of KPV. Not in a human, not in any species. That is the form with the best marketing.

The registry is empty. Search ClinicalTrials.gov for KPV and you get nothing. Search Lys-Pro-Val and you get four amino acid studies and seven irrelevant entries. A 2023 review of this peptide family says human experience with it is anecdotal and names PL-8177 as the only member to reach a trial. (PMID 37508552) FDA's own reviewers grouped KPV with TB-500 and MOTS-c as peptides with no human clinical trials available.

So any NCT number you are shown for KPV is not a KPV trial. It may well come from the cluster of eight fabricated registrations under the sponsor Hudson Biotech, all at one hospital in Shenzhen, all registered in February 2026, one carrying "(Mock Study)" in its own title and two more copying Eli Lilly trial titles. Morgan McSweeney published the investigation on 31 July 2026 and confirmed Lilly has no relationship with the sponsor. (Dr Noc)

The July 2026 vote. FDA's Pharmacy Compounding Advisory Committee voted on seven peptides on 23 and 24 July under Docket No. FDA-2025-N-6895, deciding which ingredients pharmacies may legally compound with. FDA's own reviewers recommended against all seven for insufficient clinical evidence. KPV got a majority anyway, 8 for, 6 against, 1 abstaining. The vote is not binding and nothing changes until FDA finalises a rule.

Where the dose came from

The widely shared community sheet says 200 to 400 mcg a day injected, 250 mcg twice daily by mouth, and 7.5 mg twice daily on the skin, with a 5 mg vial lasting 25 days. That page says outright that it is compiling anecdotes and expert opinion, because there are no human trials.

I cannot trace any of those numbers to anything. The only figure in the whole literature that could speak to a human dose is that 16 mcg per kg per day in mice, which for a 70 kg adult would be 1,120 mcg if you scaled it straight across. You do not scale it straight across. The standard method divides the mouse dose by 12.3 to account for how much faster a small animal runs its metabolism, which gives about 1.3 mcg per kg, or roughly 90 mcg a day for a 70 kg human.

That is five to ten times below what vendors recommend by mouth. And it came from a mouse getting nanoparticles down a feeding tube.

What nobody knows

What it does in a body. No human pharmacokinetics, absorption or half life, for any route. Vendor pages say the half life is short and cite nothing.

Whether anyone has used it and reported back. No published case series.

Whether the skin claim holds. The positive topical findings come from films laid on surgical wounds in diabetic mice, and I could not locate the paper being cited for them.

Where the cycling schedules came from. The 8 on 8 off and 5 on 2 off patterns appear on vendor pages with no source behind them.

My thoughts

The most honest thing I can say about KPV is that it is a local gut treatment for rodents that works through a food transport system, and every study that got a result built a delivery vehicle to put it where it needed to be.

Of the three forms being sold, the injection has the best marketing and the worst evidence, which is none, in any species.

The 2003 experiment should have ended this twenty-three years ago. Somebody put the fragment next to the parent, in the same cells, on the same day, and the fragment did nothing the parent did. That paper still turns up in the opening paragraph of product pages, cited as support.

If I were going to use it, I would take it by mouth, for a diagnosed gut problem, because that is the only thing the published work is actually about.

The comparison I keep coming back to is TB-500, which is also a fragment sold on its parent's reputation. The difference is that with KPV, somebody actually ran the head to head.

I would like to know whether anyone reading this bought the topical cream.

---

This content is for educational and informational purposes only and is not medical advice. Peptides discussed are research compounds and may not be approved for human use. Nothing here should be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any peptide, supplement, or protocol. Individual responses vary. Do not self-administer compounds without proper medical supervision.